<DOC>
	<DOCNO>NCT00513981</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , high-dose methotrexate work different way stop growth tumor cell , either kill cell stop dividing . Chemoprotective drug , leucovorin calcium , may protect normal cell side effect chemotherapy . PURPOSE : This phase I trial study side effect , best way give , best dose high-dose methotrexate treating patient solid tumor .</brief_summary>
	<brief_title>High-Dose Methotrexate Treating Young Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - To determine maximum tolerated time exposure high-dose methotrexate administer continuous infusion dose 6 g/m² per 24 hour . - To relate methotrexate schedule investigate magnitude duration change plasma homocysteine methionine . - To relate evidence systemic effect methotrexate change plasma homocysteine methionine hepatic , neurological , antiproliferative toxicity observe study group . OUTLINE : Patients receive continuous infusion high-dose methotrexate IV 24 , 30 , 36 , 42 hour depend time study entry . Beginning hour 42 48 , patient receive leucovorin calcium IV every 6 hour 3 day plasma methotrexate concentration &lt; 0.2 µM . Treatment repeat every 2 week absence disease progression unacceptable toxicity . Blood sample collect baseline periodically study analyzed pharmacodynamic effect plasma homocysteine methionine gas chromatography/mass spectrometry technique .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven malignancy , include limited , follow : Patients MRI finding keep diffuse intrinsic pontine glioma eligible without histological confirmation tumor type Patients diagnosis diffuse intrinsic pontine glioma eligible erlotinib hydrochloride phase I study ( CCLGNAG200509 ) Patients relapse ependymoma follow CCLG phase II study intravenous etoposide ( CCLGCNS20014 ) prior eligible discretion physician Patients relapse osteogenic sarcoma , soft tissue sarcoma , solid tumor may suitable study discretion physician Radiologically evaluable disease without bone marrow involvement PATIENT CHARACTERISTICS : Inclusion criterion : Lansky performance status ( PS ) 30100 % ( patient ≤ 12 year age ) ECOG PS ≤ 2 ( patient ≥ 13 year age ) Life expectancy ≥ 9 week ANC &gt; 1,000/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 9 g/dL Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) age Serum total bilirubin normal AST ALT ≤ 2 time ULN Glomerular filtration rate ≥ 60 mL/min Negative pregnancy test Fertile patient must use effective contraception Exclusion criterion : Poor medical risk nonmalignant systemic disease uncontrolled infection Concurrent malignancy sit PRIOR CONCURRENT THERAPY : Inclusion criterion : Prophylactic trimethoprimsulfamethoxazole must stop 1 week prior methotrexate administration Exclusion criterion : Received chemotherapy biologic therapy within past 4 week Received radiotherapy within past 6 week</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
</DOC>